Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 21 min ago
Peer-reviewedCC BY 4.0International Journal of Hematology

Characteristics of progressive multifocal leukoencephalopathy in hematological malignancies, With reference to HIV-infected patients

  • Emi Yokoyama1
  • Taisuke Harada2
  • Tomoyuki Endo3
  • Hideki Goto4
  • Junichi Sugita5
  • Masayuki Aiba5
  • Mutsumi Takahata6
  • Takuto Miyagishima7
  • Hajime Senjo7
  • Satoshi Iyama8
  • Shuichiro Takahashi9
  • Masayo Yamamoto9
5 more authors
  • Motohiro Shindo9
  • Kazuya Sato10
  • Junichi Hashiguchi11
  • Tatsuo Oyake12
  • Takanori Teshima13
13 affiliations
  1. 1Blood Disorders Center, Aiiku Hospital, Sapporo, Japan
  2. 2Department of Diagnostic Imaging, Hokkaido University Hospital, Sapporo, Japan
  3. 3Department of Infection Control and Prevention, Hokkaido University Hospital, Sapporo, Japan
  4. 4Department of Hematology, Hokkaido University Hospital, Sapporo, Japan
  5. 5Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan
  6. 6Department of Hematology, Sapporo Kosei General Hospital, Sapporo, Japan
  7. 7Department of Hematology, Kushiro Rosai Hospital, Kushiro, Japan
  8. 8Department of Hematology, Sapporo Medical University Hospital, Sapporo, Japan
  9. 9Division of Hematology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa, Japan
  10. 10Department of Hematology/Oncology, Asahikawa Kosei General Hospital, Asahikawa, Japan
  11. 11Department of Hematology, Kitami Red Cross Hospital, Kitami, Japan
  12. 12Division of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Japan
  13. 13Department of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan
Read full textPDFDOICite

Abstract

Progressive multifocal leukoencephalopathy (PML) is a rare opportunistic infection of the central nervous system (CNS) observed in immunocompromised individuals. We retrospectively evaluated the clinical courses of PML in patients with hematological malignancies at North Japan Hematology Study Group institutions, using patients with human immunodeficiency virus (HIV) infection as a reference. Eight PML patients had hematological malignancies and 9 had HIV infection. CD4 + T cell counts were markedly low in patients with hematological malignancies (median 168/μl, range 48.4–330/μl) and did not differ significantly from those in patients with HIV infection (median 28/μl, range 8–225.4/μl). IgG levels were significantly lower in patients with hematological malignancies (median 643.5 mg/dL, range 205–2478 mg/dL) than in patients with with HIV infection (median 1691.5 mg/dL, range 1304–3014 mg/dL) (p < 0.01). Almost all patients with hematological malignancies died after progression of PML (median time from onset to death, 136 days). In contrast, seven patients with HIV infection were alive at the end of follow-up. The incidence of PML in patients with hematological malignancies may increase with the introduction of new antibody drugs and cellular therapies in future. Considering the poor prognosis, greater caution is warranted regarding this serious complication.

Related

  1. Treatment of Progressive Multifocal Leukoencephalopathy With Third-Party Allogeneic BK Virus T Cells
    Amanda Olson, Ye Li, David Marin +25
    Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of AmericaPeer-reviewedCC BY 4.0Full textClinical trials & evidence synthesisPMC
  2. Progressive multifocal leukoencephalopathy, bispecific antibodies, and multiple myeloma: a case report and systematic review of the literature
    Marina Tzanni, Panagiotis Polyzoidis, Konstantinos Angelopoulos +9
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossref
  3. PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY DURING TECLISTAMAB THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Sabrina NAVROSKI, Pedro D'elia Machado SILVA, Erica Marquardt Lammerhirt OTTONI +1
    Hematology, Transfusion and Cell TherapyPeer-reviewedCC BYFull textOncologyDOAJ
  4. Vaccination of patients with hematological malignancies: barriers and strategies to improve uptake
    Toni Valković, Paolo Salamon, Vanja Vasiljev +1
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Correlates of Caregiver Burden Among Informal Caregivers of Patients With Hematological Malignancies: The Roles of Coping, Resilience, and Perceived Social Support
    Nasrin Akhter, Amin Lutful Kabir, Adnan Hasan Masud +7
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{yokoyama2026characteristics,
  title = {{Characteristics of progressive multifocal leukoencephalopathy in hematological malignancies, With reference to HIV-infected patients}},
  author = {Emi Yokoyama and Taisuke Harada and Tomoyuki Endo and Hideki Goto and Junichi Sugita and Masayuki Aiba and Mutsumi Takahata and Takuto Miyagishima and Hajime Senjo and Satoshi Iyama and Shuichiro Takahashi and Masayo Yamamoto and Motohiro Shindo and Kazuya Sato and Junichi Hashiguchi and Tatsuo Oyake and Takanori Teshima},
  journal = {International Journal of Hematology},
  year = {2026},
  month = jul,
  doi = {10.1007/s12185-026-04256-5},
  url = {https://doi.org/10.1007/s12185-026-04256-5},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Characteristics of progressive multifocal leukoencephalopathy in hematological malignancies, With reference to HIV-infected patients
AU  - Emi Yokoyama
AU  - Taisuke Harada
AU  - Tomoyuki Endo
AU  - Hideki Goto
AU  - Junichi Sugita
AU  - Masayuki Aiba
AU  - Mutsumi Takahata
AU  - Takuto Miyagishima
AU  - Hajime Senjo
AU  - Satoshi Iyama
AU  - Shuichiro Takahashi
AU  - Masayo Yamamoto
AU  - Motohiro Shindo
AU  - Kazuya Sato
AU  - Junichi Hashiguchi
AU  - Tatsuo Oyake
AU  - Takanori Teshima
PY  - 2026
DA  - 2026/07/24
JO  - International Journal of Hematology
DO  - 10.1007/s12185-026-04256-5
UR  - https://doi.org/10.1007/s12185-026-04256-5
AB  - Progressive multifocal leukoencephalopathy (PML) is a rare opportunistic infection of the central nervous system (CNS) observed in immunocompromised individuals. We retrospectively evaluated the clinical courses of PML in patients with hematological malignancies at North Japan Hematology Study Group institutions, using patients with human immunodeficiency virus (HIV) infection as a reference. Eight PML patients had hematological malignancies and 9 had HIV infection. CD4 + T cell counts were markedly low in patients with hematological malignancies (median 168/μl, range 48.4–330/μl) and did not differ significantly from those in patients with HIV infection (median 28/μl, range 8–225.4/μl). IgG levels were significantly lower in patients with hematological malignancies (median 643.5 mg/dL, range 205–2478 mg/dL) than in patients with with HIV infection (median 1691.5 mg/dL, range 1304–3014 mg/dL) (p < 0.01). Almost all patients with hematological malignancies died after progression of PML (median time from onset to death, 136 days). In contrast, seven patients with HIV infection were alive at the end of follow-up. The incidence of PML in patients with hematological malignancies may increase with the introduction of new antibody drugs and cellular therapies in future. Considering the poor prognosis, greater caution is warranted regarding this serious complication.
SN  - 0925-5710
SN  - 1865-3774
ER  -